Proceeds used to fully repay USD 750 million equivalent in USD and EUR term loans and extend debt maturities to 2035, while reducing overall interest expenses Basel, March 31, 2025 – Sandoz (SIX ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

Spain's competition watchdog opened an investigation into whether drug makers including Sandoz and its subsidiary Bexal broke antitrust rules by sharing sensitive commercial information.

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster ...

Investing.com -- Barclays analysts see potential upside in Sandoz AG (SIX:SDZ) shares, arguing that tariff risks are now largely priced into the stock. Despite the company’s underperformance ...

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

The peculiarity of the situation is that Novartis is now unable to recoup biosimilars — since the separation of Sandoz, it has withdrawn from this business and is unable to compensate for the ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Sandoz: This Swiss-based generic drugmaker used to be a subsidiary of Novartis before being spun off in 2023.

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of ...

53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology ...